NCT06349837 2025-12-17Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky TumorsSichuan UniversityPhase 1 Recruiting24 enrolled
NCT05833984 2023-04-27Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and LymphomasImmuneOnco Biopharmaceuticals (Shanghai) Inc.Phase 1/2 Unknown309 enrolled